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Abstract
Background: Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (osteoprotegerin,
OPG) play a pivotal role in bone remodeling by regulating osteoclasts formation and activity. RANKL stimulates migration of
RANK-expressing tumor cells in vitro, conversely inhibited by OPG.
Materials and Methods: We examined mRNA expression levels of RANKL/RANK/OPG in a publicly available microarray
dataset of 295 primary breast cancer patients. We next analyzed RANK expression by immunohistochemistry in an
independent series of 93 primary breast cancer specimens and investigated a possible association with clinicopathological
parameters, bone recurrence and survival.
Results: Microarray analysis showed that lower RANK and high OPG mRNA levels correlate with longer overall survival
(P = 0.0078 and 0.0335, respectively) and disease-free survival (P = 0.059 and 0.0402, respectively). Immunohistochemical
analysis of RANK showed a positive correlation with the development of bone metastases (P = 0.023) and a shorter skeletal
disease-free survival (SDFS, P = 0.037). Specifically, univariate analysis of survival showed that ‘‘RANK-negative’’ and ‘‘RANK-
positive’’ patients had a SDFS of 105.7 months (95% CI: 73.9–124.4) and 58.9 months (95% CI: 34.7–68.5), respectively. RANK
protein expression was also associated with accelerated bone metastasis formation in a multivariate analysis (P = 0.029).
Conclusions: This is the first demonstration of the role of RANK expression in primary tumors as a predictive marker of bone
metastasis occurrence and SDFS in a large population of breast cancer patients.
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Introduction
Bone is the most common site of metastatic invasion in breast
cancer. Skeletal metastases from breast cancer are mostly
osteolytic, with histological evidence of increased number and
activity of bone-resorbing osteoclasts. However, the molecular
mechanisms of breast cancer metastasis to the skeleton are still
poorly understood. Recently, a novel cytokine triad consisting of
receptor activator of NF-kB ligand (RANKL), its receptor (RANK)
and the endogenous decoy receptor osteoprotegerin (OPG) was
identified and extensively characterized for its role in bone
remodeling. It is well known that RANK/RANKL/OPG axis
controls osteoclastogenesis and bone resorption [1].
The TNF ligand superfamily member RANKL, which is
expressed on the surface of osteoblasts, is critical for the formation,
function and survival of osteoclasts [2,3]. It exerts its functions by
binding and activating its receptor RANK [4,5], which is
expressed on the surface of osteoclastic precursors and mature
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osteoclasts [6]. OPG is a soluble member of the TNF receptor
super family secreted by osteoblasts which, by competing with
RANK for binding to RANKL, acts as a decoy receptor, thereby
inhibiting osteoclastogenesis [7]. Alterations of the RANKL/OPG
balance have been reported in a spectrum of skeletal diseases
characterized by excessive osteoclastic activity, including osteopo-
rosis, rheumatoid arthritis and bone metastases. RANK expression
is not restricted to bone, as it is also observed in other tissues
including breast, lung, brain, kidney and cartilage. Moreover, the
RANKL/RANK/OPG system is disregulated in several tumors,
such as breast cancer, malignant bone tumors, multiple myeloma,
giant cell tumors of bone, chondroblastoma, neuroblastoma and
squamous cell carcinoma [8–14]. Recently, functional RANK
expression was reported in cancer cell lines from human origin
(osteosarcoma, breast and prostate carcinomas) [15,16], and in
mouse melanoma cell lines [16]. RANK/RANKL expression was
also found in resected specimens obtained from breast, hepato-
cellular and prostate cancer and multiple myeloma. In breast,
RANKL and RANK are expressed in the normal tissue and,
conversely to RANK, an apparent loss of RANKL expression
occurs in neoplastic tissue. However, breast tumors retaining
RANKL expression tend to be less differentiated and estrogen
receptor negative [17]. In prostate, RANKL/RANK expression is
low in normal tissue but high in neoplastic tissues and even higher
in metastatic lesions [18,19]. Finally, Sasaki et al examined cases of
primary hepatocellular carcinoma (HCC), showing that RANKL
expression in HCC cells correlated with the development of bone
metastasis after hepatic resection [20].
On the basis of a high constitutive RANK expression in breast
cancer specimens and cell lines, recent data suggest that the
RANK status in cancer cells determines their tendency to
metastasize to bone whereas RANKL is abundantly expressed
[16]. This hypothesis is supported by the observation that RANKL
induces the migration of various RANK-expressing cancer cell
lines in vitro, in a manner that is blocked by RANKL inhibitors
(OPG or sRANK/RANK-Fc). Moreover, OPG treatment of
tumor-bearing animals prevents the homing of RANK-expressing
B16F10 melanoma cells in bone [16]. Moreover, increased
RANKL expression is related to migration and metastatic
propensity of prostate tumor cells and renal cell carcinomas
[21,22]. Thus, the RANKL/RANK pathway may dictate breast
cancer cells to preferentially migrate into bone. To the best of our
knowledge, there are not previous studies which investigated a
large and homogeneous cohort of breast cancer patients about the
role of RANK expression in primary cancer cells in predicting
bone metastatization.
Specifically, the main purpose of our research was to
demonstrate the potential role of RANK expression in primary
tumors as a predictive marker of bone metastasis occurrence and
skeletal disease-free survival (SDFS) in a population of breast
cancer patients.
Results
Microarray analysis: RANK/RANKL/OPG pathway and
clinicopathological prognostic factors
The correlation between RANK, OPG and RANKL levels with
the clinico-molecular prognostic factors available for the NKI
cohort (Table 1) was analyzed. On the basis of RANK level
distribution, basal tumors have higher expression compared to all
the other molecular subtypes (Figure 1A) and the difference is
strongly significant (P,0.0001) comparing basal- versus non basal-
type tumors (Figure 1B).
No correlation was found between age (,50 and $50 years)
and the expression of any of the three molecules (data not shown).
Regarding tumor size, we found a statistically significant difference
between tumor #2 cm and .2 cm in RANK and RANKL at
transcriptional level (Figure 1C), whereas OPG levels are not
significantly correlated with size. All the three parameters are
strongly associated with histological grading (Figure 1D). RANK
levels are lower in well differentiated (G1) than intermediate (G2)
and poorly differentiated (G3) tumors. In particular, a statistically
significant difference is observed between G1 and G3 (P,0.01).
Conversely, OPG and RANKL level are higher in G1 tumors than
G2 and G3 (P,0.05 for RANKL and P,0.01 for OPG,
comparing G1 and G3). Interestingly, dividing the population in
‘‘poor prognosis’’ and ‘‘good prognosis’’ group on the basis of the
70-gene signature, RANK expression is significantly higher in the
‘‘poor’’ versus ‘‘good prognosis’’ group (P=0.01), while RANKL
and OPG levels are higher in the ‘‘good prognosis’’ versus ‘‘poor
prognosis’’ (P=0.003 and 0.0005, respectively) (Figure 1E).
Importantly, ER negative tumors RANK expression is significant-
ly higher (P,0.0001), but RANKL and OPG do not show a
significant difference between the two groups (Figure 1F).
Univariate analysis of survival in microarray study
Kaplan Meier curve showed a significant correlation between
low RANK levels and longer overall survival (OS) (P=0.0078)
(Figure 2B). Patients with low level of RANK tend to have a better
disease free survival (DFS), although the significance is not
observed in this dataset (P=0.059) (Figure 2A). Regarding
RANKL expression, we did not find any statistically significant
Table 1. Clinico-molecular characteristics of 295 breast
cancer patients from NKI microarray dataset.
Parameter pts (n) pts (%)
Age (ys)
,50 246 83.4
$50 49 16.6
Positive nodes (n)
0 151 51.2
1–3 106 35.9
$4 38 12.9
Size (cm)
#2 155 52.5
.2 140 47.5
Histological grade
Well differentiated (G1) 75 25.5
Intermediate (G2) 101 34.2
Poor (G3) 119 40.3
ER status
Negative 69 23.4
Positive 226 76.6
70-gene signature
Poor prognosis 180 61
Good prognosis 115 39
Clinico-molecular characteristics of 295 breast cancer patients from NKI cohort
(24). Raw data and complete clinical data were downloaded from the Rosetta
Web site (http://www.rii.com).
doi:10.1371/journal.pone.0019234.t001
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correlation neither with DFS nor OS (data not shown). Patients
with higher level of OPG present a longer DFS (P=0.040) and OS
(P=0.033) than patients with lower OPG (Figure 2C and 2D).
Experimental phase: RANK expression and
clinicopathological characteristics in breast cancer
patients
Among RANKL/RANK/OPG, RANK resulted to be more
strikingly and consistently correlated both with clinical prognostic
factors and survival. Therefore, we performed IHC for RANK in
our independent series of 77 IDC samples and 15 ILC samples.
RANK overexpression was found in 39% (30/77) IDC and in
53% (8/15) ILC samples (Figure 3, Table 2). 35% (22/63) patients
with N0 or N1 node status were RANK-positive, whereas 55%
(16/29) patients with N2 or N3 node status were RANK-positive.
The only G1 sample was RANK-negative, whereas 35% (15/43)
of G2 samples and 55% (16/43) of G3 samples were positive for
RANK expression. Only 36% (9/25) HER2/neu positive samples
were RANK-positive, whereas 40% (22/55) HER2/neu negative
samples were RANK-positive and 54% (7/13) patients without a
Figure 1. RANK/RANKL/OPG pathway, molecular and clinicopathological prognostic factors in 295 early breast cancer patients
from NKI microarray dataset. Tukey whisker plots indicate the correlation between normalized mRNA level of RANK/RANKL/OPG and prognostic
factors in a cohort of 295 primary breast cancer patients from NKI (34). Panel A: basal tumors present a higher expression of RANK mRNA compared
to all the other molecular subtypes. Panel B: this difference is strongly significant comparing basal- versus non basal-type tumors. Panel C: we
found a statistically significant difference between tumor #2 cm and .2 cm in RANK and RANKL. Panel D: RANK/RANKL/OPG are strongly
associated with histological grading. Panel E: dividing the population in ‘‘poor prognosis group’’ and ‘‘good prognosis group’’ on the basis of the 70-
gene signature, RANK expression is significantly higher in the ‘‘poor prognosis’’ versus ‘‘good prognosis’’ group, while RANKL and OPG levels are
higher in the ‘‘good prognosis’’ versus ‘‘poor prognosis’’. Panel F: RANK expression is significantly higher in ER negative tumors. RANKL and OPG do
not show a significant difference between the two groups. P values are indicated as: * P=,0.05, ** P=,0.01, *** P,0.001, **** P,0.0001.
doi:10.1371/journal.pone.0019234.g001
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known HER2/neu were RANK-positive. 31% (10/32) samples
from cases without metastases were RANK-positive, whereas
31% (5/16) samples from patients with visceral metastases were
positive for expression of RANK in the tumor cells. Moreover,
31% (5/16) samples from patients with bone metastasis were
RANK-positive as well as 62% (18/29) samples from patients
with bone and visceral involvement. RANK expression was
independent from histotype (P= 0.23), HER2/neu expression
(P=0.47) and grading (P=0.39), but his positivity was associated
with lymph nodes involvement (P= 0.05). However, RANK-
positive patients showed a significantly higher risk to develop
skeletal metastases (P= 0.023) (Table 2).
Moreover, RANK positivity was detected in 51.1% (23/43) of
patients who developed metastases versus 31.25% (15/48) of
patients who remained metastasis-free (P= 0.042).
Correlation of clinicopathological data with SDFS
(univariate analysis)
Univariate survival analysis did not show correlation of
histotype, grading, HER2/neu status with SDFS (data not shown).
Only nodes involvement was significantly associated with an early
skeletal recurrence (P=0.012).
RANK expression associates with accelerated bone
metastasis (univariate analysis)
To establish the skeletal prognostic role of RANK, patients were
stratified in positive (RANK-high expression) versus negative
(RANK-low expression). Univariate analysis of survival showed
that the RANK expression was associated with SDFS. Specifically,
patients with overexpression of RANK showed a shorter SDFS
58.9 months (95% C.I: 34.7–68.5) than RANK negative patients
105.7 months (95% C.I: 73.9–124.4) (P=0.034; Figure 4).
Multivariate analysis
Multivariate analysis using the Cox proportional hazards model,
demonstrated that both nodes status and RANK expression are
independent prognostic indicators for early bone metastasis
development (P=0.029 and 0.037, respectively) (Table 3).
Discussion
RANK / RANK-L is a largely studied pathway (mainly in the
preclinical setting) and that its key role in the metastatic process to
bone was hypothesized and investigated before by using in vivo
models (16,21,22). In the clinical setting, several groups found an
Figure 2. Univariate analysis of survival in microarray study. 295 primary breast cancers from NKI microarray dataset (34) were divided in
three equally numerous groups depending on the level of mRNA expression of RANK and OPG (high, medium or low). Tumors with high and medium
RANK level were grouped together and are indicated as possessing high RANK mRNA (H) vs low (L). OPG expression was dichotomized as low (L+M)
vs high (H). The Kaplan-Meier curves show the correlation between expression of RANK or OPG and DFS and OS. The curves were analyzed by Log-
rank (Mantel-Cox) Test, Hazard ratios and 95% confidence intervals (CIs) were calculated by use of a stratified Cox regression analysis. Panel A and B:
patients with low level of RANK show a better DFS (P=0.059) and a statistically significant longer OS (P= 0.0078), compared to patients with high
RANK expression. Panel C and D: patients with higher mRNA level of OPG present a longer DFS (P= 0.0402) and OS (P= 0.0335) than patients with
lower OPG.
doi:10.1371/journal.pone.0019234.g002
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association between high expression of RANK/RANKL/OPG in
the primary tumor (e.g. prostate, HCC, not in breast cancer) and
propensity to develop bone metastasis (18,20). Our group recently
demonstrated that RANK is expressed by human solid tumors
(mostly breast, colorectal, renal, lung, and prostate cancer) with
high concordance between bone metastasis and corresponding
primary tumor (23). These data highligh the central role of
RANK/RANKL/OPG pathway as therapeutic target in bone
metastasis management. The discovery of the role of RANK/
RANKL/OPG pathway in bone reabsorption produced great
expectations. A therapeutic targeting could help in preventing
skeletal related events in breast cancer patients with bone
metastases, preserving bone health in patients receiving cancer
treatments that induce bone loss (CTIBL) and reducing the risk of
disease recurrence in adjuvant setting. Herein, we report our
findings of the prognostic role of RANK/RANKL/OPG in a
microarray dataset of 295 early-stage breast cancer patients. In
particular, high RANK and low OPG levels in primary tumors
are predictive of worst prognosis. At the same time, the
expression of both genes examined was correlated with the main
clinicopathological and molecular features of primary breast
tumors. A higher RANK gene expression has been found in the
‘‘poor prognosis’’, .2 cm, estrogen receptor negative and G3
tumors. On the other hand, a higher OPG expression was found
in the ‘‘good prognosis’’ signature population and G1 tumors,
according to Poznak et al [24]. Positive correlation between OPG
and ER IHC expression in breast tumors has been reported by
Van Poznak et and Cross et al [17,24]. Conversely, RANKL
appeared to be inversely correlated with ER in IHC analysis [24].
Our microarray results do not show a significant correlation
between ER status and OPG/RANKL expression. However, a
comparison between results from two different methodic (IHC
and microarray) has intrinsic limitations. Unfortunately, we do
not have IHC data for OPG and RANKL in our series. Further
studies will be needed. There is no correlation between age and
expression of RANK, RANKL or OPG in NKI dataset.
Unfortunately, we do not possess clinical data about the
menopausal status of these patients.
Interestingly, a recent model has been proposed in which surges
of progesterone occurring during the reproductive cycle and
pregnancy prompt mammary stem cells (MaSCs) proliferation,
providing a window during which MaSCs (ER2/PR2) are targets
for oncogenic mutations [25]. This paracrine effector of
progesterone could be RANKL from luminal cells binding to its
receptor on MaSCs.
Figure 3. Immunohistochemical results in 93 breast cancers.
Image A: RANK positive breast cancer. The normal glandular
epithelium is negative (N) confirming the RANK protein overexpression
of the tumor tissue. Image B: RANK negative breast cancer (TC). Tissue-
associated macrophages (M) are positive for RANK staining and are
used as internal positive controls. Original magnification A,B 2006.
doi:10.1371/journal.pone.0019234.g003
Table 2. Correlation between clinico-pathologic parameters
and RANK expression in 93 patients with IDC or ILC.
Parameter pts (n) RANK+(%) P
Histological type
Ductal 77 30 (39) 0.23
Lobular 15 8 (53)
Unknown 1 0 (0)
Positive nodes (n)
N0–N1 63 22 (35) 0.05
N2–N3 29 16 (55)
Unknown 1 0 (0)
Histological grade
Well differentiated (G1) 1 0 (0) 0.39
Intermediate (G2) 43 15 (35)
Poor (G3) 43 16 (37)
Unknown 6 0 (0)
Hercep test
Positive 25 9 (36) 0.47
Negative 55 22 (40)
Unknown 13 7 (54)
Sites of Metastasis
Bone 16 5 (31) 0.023
Visceral 16 5 (31)
Bone+Visceral 29 18 (62)
No metastasis 32 10 (31)
Clinico-molecular characteristics of patients included in our independent series
of 93 primary breast cancer specimens used to perform RANK IHC. RANK
positivity is associated with lymph nodes involvement (P= 0.05). RANK-positive
patients show a significantly higher risk to develop skeletal metastases
(P=0.023). The association between variables was performed using the chi
square test. IDC: intraductal carcinoma; ILC: intralobular carcinoma.
IDC: intraductal carcinoma; ILC: intralobular carcinoma; pts: patients; ys: years.
doi:10.1371/journal.pone.0019234.t002
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In fact, Joshi et al. showed that both luminal and basal cells
surrounding the MaSCs niche significantly increased PR expres-
sion following treatment with 17b-oestradiol and progesterone
[26]. They also observed profound upregulation of Wnt4 and
RANKL in luminal cells as well as induction of their respective
receptors Lrp5 and Rank in the MaSC-enriched basal cell
population. To note, both RANK and WNT4a pathways are
known mediators of progesterone driven paracrine effects in the
mammary gland. Moreover, Asselin-Labat et al. found, during
mid-pregnancy, a marked increase in RANKL expression in the
luminal cell population, and the RANK receptor and the RANK
signaling target Id2 in the MaSC-enriched basal cell subset [27].
Treatment with a RANKL inhibitor suppressed the clonogenic
activity of this population.
Moreover, Beleut et al. found that RANKL elicits proliferation in
the mammary gland by a paracrine mechanism [28]. Ablation of
RANKL in the mammary epithelium blocks progesterone-induced
morphogenesis, and ectopic expression of RANKL in mammary
epithelial cells (MECs) completely rescues the PR2/2 phenotype.
Systemic administration of RANKL triggers proliferation in the
absence of PR signaling, and injection of a RANK signaling
inhibitor interferes with progesterone induced proliferation.
These findings open the scenario for a major role of RANK/
RANKL pathways in the mammary gland compartments. All
these data support the emerging prognostic role of this pathway in
breast cancer patients.
We focused the experimental phase of this study on RANK,
because of its strong correlation with clinical prognostic factors
and outcome found in the microarray analysis. NKI dataset’s
clinical annotations were lacking of the SDFS data, which we
followed in our dataset of 93 patients. We observed that higher
IHC RANK expression in primary tumors is significantly
correlated with higher risk to develop bone metastases and with
a shorter SDFS.
These results are consistent with the recent preclinical
investigations in both in vitro and in vivo murine models mimicking
bone metastatization. In fact, based on the high constitutive
RANK expression in breast cancer specimens and cell lines, recent
data suggest that RANK expression status of cancer cells
determines whether tumors predominantly migrate into bone,
whereas the corresponding ligand RANKL is abundantly
expressed. The correlation of high RANK expression with
osteotropism in murine models was demonstrated across diverse
tumor cell types, including breast cancer and melanoma [29].
Blocking RANKL-RANK signaling in these mice by OPG
administration led to a reduction of the skeletal tumor burden
Figure 4. RANK expression associates with accelerated bone metastasis in 93 breast cancer patients (Kaplan Meyer curves of SDFS).
RANK negative patients showed a SDFS of 105.7 months (95% C.I: 73.9–124.4) compared with only 58.9 months (95% C.I: 34.7–68.5) in RANK positive
patients. The difference is statistically significant (P= 0.034).
doi:10.1371/journal.pone.0019234.g004
Table 3. Multivariate analysis of skeletal disease free survival.
RR 95% C.I. P
RANK
High Expression 1 - 0.037
Low expression 0.211 0.120–0.855
Nodal Status
N1 1 - 0.029
N0 0.512 0.273–0.952
Nodes status and RANK expression are independent prognostic indicators for
early bone metastasis development (P= 0.029 and 0.037, respectively).
C.I., Confidential Interval; RR: relative risk.
doi:10.1371/journal.pone.0019234.t003
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by 50% and prevented tumor-induced paralysis [29]. For these
reasons, according to our original discoveries, we can support a
potential important functional role of RANK expression on
primary breast cancer in the complex bone metastatization
process.
In order to identify potential molecular mechanisms involved
in determining the site of relapse, Smid et al. [30] mapped
differentially expressed genes from 107 primary breast tumors
from lymph node negative patients at the time of diagnosis
which experienced relapse. A panel of 69 genes was identified as
significantly differentially expressed between patients who
relapsed to bone versus those who relapsed elsewhere. The
most differentially expressed gene was TFF1. Another approach
was used by Kang et al. in order to find mediators of breast
cancer metastasis to bone by using MDA-MB-231 cells [31].
Over-expression of the bone metastasis specific gene set (named
genes encoding C-X-C chemokine receptor [CXCR]4, IL-11,
connective tissue growth factor, and matrix metalloproteinase
[MMP]-1), along with the osteopontin gene and five genes
members of FGF receptor pathway (FGF5, SOS1, DUSP1,
FGFR3, and DUSP4) in various combinations, considerably
enhanced the metastatic potential of breast cancer cells to bone.
Anyway, each of these genes, when expressed individually, failed
to confer high skeletal tropism. However, many of the identified
classifiers and gene targets in the various studies are largely non-
overlapping, raising questions about their biologic significance
and clinical implications. Other studies have reported similar
gene expression-based approaches [21,32]. Thanks to our two-
steps approach, we observe that RANK expression has a
prognostic value in a microarray dataset of a breast cancer
population, even though the lack of availability of SDFS in that
dataset was a limit. However, our IHC results are the first
demonstration of the role of RANK expression in primary
tumors as a predictive marker of bone metastasis occurrence
and SDFS in a large population of breast cancer patients. We
think that our findings can be considered a trigger for
perspective larger studies in this setting.
Conclusions
Many studies strongly examined and confirmed the link
between RANK/RANKL/OPG pathway and propensity to
metastasize to the bone. Investigating the RANK/RANKL/
OPG pathway might open new scenarios in predicting bone
disease recurrence and prognosis and potentially preventing bone
metastatization in RANK-expressing early breast cancer patients.
The availability of a monoclonal antibody toward RANKL
(denosumab) strengthens the clinical relevance of this work.
Denosumab is a breakthrough fully human monoclonal antibody
now approved by both the FDA and EMA. It had been fast
tracked by FDA for treatment and prevention of postmenopausal
osteoporosis, and treatment and prevention of bone loss in
hormone treated prostate and breast cancer patients [33,34]. The
modulation of the gene and protein expression trough anti-
RANKL therapy at primary tumor level might modify the
physiopathology of bone metastases. In this regard, our work
represents a strong biological rational supporting the ongoing
randomized, double-blind, placebo-controlled, multi-center phase
3 study evaluating Denosumab as adjuvant treatment for women
with early-stage breast cancer at high risk of recurrence. In the
next future Denosumab could be tested to verify the role of
RANKL/RANK pathway in preventing skeletal migration and
metastases in the subpopulation of RANK expressing early breast
cancer patients.
Materials and Methods
Microarray analysis
We used one publicly available microarray dataset of 295
patients with primary breast cancer from NKI cohort [35]. Raw
data and complete clinical data were downloaded from the
Rosetta Web site (http://www.rii.com). Clinico-molecular char-
acteristics of the patients are shown in Table 1.
Raw data have been imported in Partek Genomic Suite 6.4
software (Partek Inc., St. Louis, MO), transformed in log2 and
normalized by quantile normalization. Principal Component
Analysis (PCA) was used to verify the quality of data. The log2
transformed data for the following probe sets have been evaluated:
RANK, RANKL, OPG. Population has been stratified on basis of
the main available prognostic factors for breast cancer: Estrogen
Receptor (ER) status, tumor size and histological grading.
Moreover, the 70-gene prognostic profile (van’t Veer signature)
has been used to divide the population in ‘‘Good prognosis’’ and
‘‘Poor prognosis’’ group. The classification in molecular subtypes
by Sorlie et al. has been also considered [36].
Patients of the experimental phase
We investigated RANK expression in primary tumors by
immunohistochemistry (IHC) and its possible association with
clinicopathological parameters, bone recurrence and survival. The
study retrospectively enrolled women with confirmed histological
diagnosis of breast cancer who underwent radical surgery. In
particular, surgical biopsy samples of 93 patients with intraductal
carcinoma (IDC) or intralobular carcinoma (ILC) were retrieved
from the surgical archives of the histopathology departments of
Campus Bio-Medico University (Roma), Institute for Cancer
Research and Treatment (Torino), ‘‘Ospedale S.Giovanni di Dio’’
(Napoli), ‘‘Policlinico S.Matteo’’ (Pavia), ‘‘Ospedale di Galliera’’
(Genova) and ‘‘Ospedale Fatebenefratelli’’ (Milano). The study
was approved by the Institutional Review Boards of the above
mentioned institutions/hospitals. No informed consent statement
from patients was obtained, since samples collected at the moment
of the diagnosis were retrospectively retrieved, made anonymous
and coded. The ethics committees approved this procedure.
Key inclusion criteria were the availability of a follow-up at least
of 24 months from the surgery and absence of metastatic disease at
the diagnosis of primary tumors. Exclusion criteria were
neoadjuvant therapy and not sufficient tissue available for IHC.
All patient records were collected into a common database. A
complete patient record contained information on clinicopatho-
logical features of the tumor site of recurrences, SDFS and OS.
Follow-up data were available for all the cases, with a median
follow-up of 43 months. Clinicopathological information were
retrieved from the pathology and medical records; patients were
stratified into four groups: 1) patients who developed bone lesions
as first metastatic site; 2) patients who developed bone lesions after
the appearance of visceral metastasis, 3) and 4) patients who did
not develop bone metastasis (only visceral metastasis and without
any metastases, respectively). Detailed clinical data of these
patients are provided in Table 2.
Immunohistochemical analysis
Representative tumor blocks were sectioned at 3 mm thickness.
IHC was performed by the streptavidin-biotin method. Endoge-
nous peroxidase in the section was blocked by incubating them in
3% hydrogen peroxide. A mouse monoclonal antibody against
RANK protein (clone 80707, R&D Systems, Inc.) was used at
concentration of 25 mg/mL. This antibody has been used and
validated previously by our group and others [23,37]. Sections
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were incubated with LSAB2 (Dakocytomation). 3-39-diaminoben-
zidine (DAB) was used for color development and haematoxylin
was used for counterstaining. Scoring for RANK was based on
relative intensities of staining of tumor cells with reference to the
normally present RANK staining of tissue associated macrophag-
es. These internal references were used as internal positive controls
between slides and samples as well as for the staining procedure.
Notably, we performed additional immunofluorescence experi-
ments on formalin fixed and paraffin embedded tissue sections to
further validate our internal positive control, in particular the
ability of the anti-RANK antibody to bind to macrophages
(Figures S1 and S2).
Cancer lesions tissue was then evaluated by comparison with the
internal controls. Staining intensity was graded as absent (0),
positive but less (+1), like (2+) or more (3+) intense than internal
control tissue. Samples with regions of heterogeneous staining
intensities were scored and the percentage of staining intensity for
each area was recorded. Overexpression of RANK protein was
considered when neoplastic cells showed 2+ and 3+ immunostain-
ing intensity. The average number of tumor cells overexpressing
RANK was ,50% (48,3%), therefore 50% was chosen as cut-off
for binomial classification of tumor samples. An immunostaining
intensity of 2+ and 3+ in more than 50% of cancer cells was
considered as the cut-off point to consider a sample as ‘‘positive’’.
Immunostaining was assessed by two independent pathologists
blinded to clinical characteristics and outcomes. Agreement in
immunohistochemical evaluation between the two observers was
.90% (Kappa value: 0.961).
Statistical analysis
Log2 normalized expression data for RANK/RANKL/OPG
probesets have been compared in the different groups by using the
unpaired t test and one-way ANOVA test (for two unpaired groups
or more than two groups, respectively).
Descriptive analyses were performed using the median values
and the corresponding 95% Confidence Interval (CI). The
association between variables in the 93 patients dataset was
performed using the chi square test.
In order to analyze the correlation between RANK/RANKL/
OPG pathway and outcome in 295 breast cancer patients we
divided the population in three equally numerous groups
depending on the expression level of each probesets (high,
medium or low), according to previously used methods [38].
For the survival analysis, tumors with high (H) and medium (M)
RANK mRNA level were grouped together and are indicated as
possessing high RANK (H) vs low RANK (L). OPG expression
was dichotomized as low (L+M) vs high (H).
DFS and SDFS analysis were calculated as the period from the
date of diagnosis to the first observation of any metastasis and
bone metastases, respectively. The OS time was calculated as the
period from the date of diagnosis until death from any cause or last
follow-up. Univariate analysis of OS, DFS and SDFS has been
estimated according to the Kaplan-Meier method and analyzed by
Log-rank (Mantel-Cox) Test [39]. Hazard ratios and 95%
confidence intervals (CIs) were estimated by use of a stratified
Cox regression analysis.
The Cox proportional hazards model was applied to the
multivariate survival analysis [40].
Statistical analysis has been performed with GraphPad Prism
software version 5.00 (GraphPad Software Inc., San Diego, CA,
USA) and SPSS software (version 17.00, SPSS, Inc.). A two-sided
P-value,0.05 has been considered statistically significant.
Supporting Information
Figure S1 Immunofluorescence staining with anti-
RANK and anti-CD68 antibodies of a breast cancer
section. A RANK positive breast cancer section was stained with
anti-RANK (B, green) and anti-CD68 (C, red) antibodies. The
merged image (D) shows that the CD68 positive cell is also positive
for RANK, confirming RANK expression by macrophages.
(A) =DAPI staining.
(TIF)
Figure S2 Immunofluorescence staining with anti-CD68
and anti-AE1-AE3 cytokeratin antibodies of a breast
cancer section. Immunofluorescence staining for CD68 (red)
and AE1-AE3 cytokeratin (green) antibodies shows staining that
macrophages are completely negative to AE1-AE3 antibody.
(TIF)
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